Receptors, TNF-Related Apoptosis-Inducing Ligand

"Receptors, TNF-Related Apoptosis-Inducing Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumor necrosis factor receptor family members that are widely expressed and play a role in regulation of peripheral immune responses and APOPTOSIS. The receptors are specific for TNF-RELATED APOPTOSIS-INDUCING LIGAND and signal via conserved DEATH DOMAINS that associate with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.

Descriptor ID	D053220
MeSH Number(s)	D12.776.543.750.690.600 D12.776.543.750.705.852.760.396
Concept/Terms	Receptors, TNF-Related Apoptosis-Inducing Ligand Receptors, TNF-Related Apoptosis-Inducing Ligand Receptors, TNF Related Apoptosis Inducing Ligand Tumor Necrosis Factor Receptor Superfamily, Member 10 TRAIL Receptors Receptors, TRAIL Receptors, Tumor Necrosis Factor, Member 10 TNF-Related Apoptosis-Inducing Ligand Receptors TNF Related Apoptosis Inducing Ligand Receptors Receptors, Tumor Necrosis Factor, Member 10d Receptors, Tumor Necrosis Factor, Member 10d Decoy Receptor 2, Tumor Necrosis Factor Receptor, TRAIL-4 Receptor, TRAIL 4 TRAIL-4 Receptor DCR2 Receptor Receptor, DCR2 CD264 Antigen Antigen, CD264 TRAIL Receptor 4 Receptor 4, TRAIL Receptors, Tumor Necrosis Factor, Member 10a Receptors, Tumor Necrosis Factor, Member 10a Tumor Necrosis Factor Receptor Superfamily, Member 10a APO2 Receptor Receptor, APO2 Receptor, TRAIL-1 Receptor, TRAIL 1 TRAIL-1 Receptor TRAIL Receptor 1 DR4 Receptor Receptor, DR4 CD261 Antigen Antigen, CD261 Death Receptor-4 Death Receptor 4 Receptor-4, Death Receptors, Tumor Necrosis Factor, Member 10b Receptors, Tumor Necrosis Factor, Member 10b TRAIL Receptor 2 Receptor, TRAIL-2 Receptor, TRAIL 2 TRAIL-2 Receptor DR5 Receptor Receptor, DR5 Tumor Necrosis Factor Receptor Superfamily, Member 10b TNF-Related Apoptosis-Inducing Ligand Receptor 2 TNF Related Apoptosis Inducing Ligand Receptor 2 CD262 Antigen Antigen, CD262 Death Receptor-5 Death Receptor 5

Below are MeSH descriptors whose meaning is more general than "Receptors, TNF-Related Apoptosis-Inducing Ligand".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptors, Death Domain [D12.776.543.750.690]
Receptors, TNF-Related Apoptosis-Inducing Ligand [D12.776.543.750.690.600]
Receptors, Immunologic [D12.776.543.750.705]
Receptors, Cytokine [D12.776.543.750.705.852]
Receptors, Tumor Necrosis Factor [D12.776.543.750.705.852.760]
Receptors, TNF-Related Apoptosis-Inducing Ligand [D12.776.543.750.705.852.760.396]

Below are MeSH descriptors whose meaning is related to "Receptors, TNF-Related Apoptosis-Inducing Ligand".

Below are MeSH descriptors whose meaning is more specific than "Receptors, TNF-Related Apoptosis-Inducing Ligand".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptors, TNF-Related Apoptosis-Inducing Ligand" by people in this website by year, and whether "Receptors, TNF-Related Apoptosis-Inducing Ligand" was a major or minor topic of these publications.

Bar chart showing 48 publications over 20 distinct years, with a maximum of 6 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	1	1
2000	0	4	4
2001	0	4	4
2002	0	3	3
2003	0	2	2
2004	0	5	5
2005	0	6	6
2006	0	1	1
2007	1	0	1
2008	1	1	2
2009	2	2	4
2010	0	2	2
2011	3	1	4
2012	1	1	2
2013	0	1	1
2015	1	1	2
2016	1	0	1
2017	1	0	1
2018	0	1	1
2021	1	0	1

Below are the most recent publications written about "Receptors, TNF-Related Apoptosis-Inducing Ligand" by people in Profiles.

Nalawade SA, Shafer P, Bajgain P, McKenna MK, Ali A, Kelly L, Joubert J, Gottschalk S, Watanabe N, Leen A, Parihar R, Vera Valdes JF, Hoyos V. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J Immunother Cancer. 2021 11; 9(11).

View in: PubMed
Hayes-Jordan AA, Ma X, Menegaz BA, Lamhamedi-Cherradi SE, Kingsley CV, Benson JA, Camacho PE, Ludwig JA, Lockworth CR, Garcia GE, Craig SL. Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor. Neoplasia. 2018 05; 20(5):524-532.

View in: PubMed
Ralff MD, Kline CLB, Küçükkase OC, Wagner J, Lim B, Dicker DT, Prabhu VV, Oster W, El-Deiry WS. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms. Mol Cancer Ther. 2017 07; 16(7):1290-1298.

View in: PubMed
Wang J, Wang H, Wang LY, Cai D, Duan Z, Zhang Y, Chen P, Zou JX, Xu J, Chen X, Kung HJ, Chen HW. Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy. Cell Death Differ. 2016 11 01; 23(11):1886-1896.

View in: PubMed
Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS. Targeting TRAIL in the treatment of cancer: new developments. Expert Opin Ther Targets. 2015; 19(9):1171-85.

View in: PubMed
Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC. TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2015 Jun 15; 21(12):2722-9.

View in: PubMed
Feng R, Tong Q, Xie Z, Cheng H, Wang L, Lentzsch S, Roodman GD, Xie XQ. Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption. Mol Carcinog. 2015 Dec; 54(12):1796-806.

View in: PubMed
Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, Wheler JJ, Sood AK, Bustinza-Linares E, Parkhurst KL, Kurzrock R. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31(5):1192-200.

View in: PubMed
Li X, Han WQ, Boini KM, Xia M, Zhang Y, Li PL. TRAIL death receptor 4 signaling via lysosome fusion and membrane raft clustering in coronary arterial endothelial cells: evidence from ASM knockout mice. J Mol Med (Berl). 2013 Jan; 91(1):25-36.

View in: PubMed
Jinesh G G, Chunduru S, Kamat AM. Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-a but not through TRAIL and FasL. J Leukoc Biol. 2012 Jul; 92(1):233-44.

View in: PubMed

People

Explore

Similar Concepts

Top Journals